Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice

Figure 7 Line plots of the variation of several lysophosphatidylcholine between the four groups. A: LysoPC [20:1 (11Z)]; B: LysoPC (16:0); C: LysoPC [18:1 (11Z)]; D: LysoPC [20:4 (5Z, 8Z, 11Z, 14Z)]; E: LysoPC [20:3 (5Z, 8Z, 11Z)]; F: LysoPC [20:5 (5Z, 8Z, 11Z, 14Z, 17Z)]; G: LysoPC (15:0); H: LysoPC [22:4 (7Z, 10Z, 13Z, 16Z)]; I: LysoPC [20:4 (8Z, 11Z, 14Z, 17Z)]; J: LysoPC (0:0/16:0); K: LysoPC (17:0); L: LysoPC [22:5 (7Z, 10Z, 13Z, 16Z, 19Z)]. ^aP < 0.01 indicates high-fat group (HFD group) vs control group, ^bP < 0.05 Sema vs HFD, ^cP < 0.05 indicates Empa vs HFD. HFD: A high-fat group; NCD: A control group.